Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085293 · ClinicalTrials.gov registry record · Phase 2
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00085293: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00085293 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085293, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase II trial is studying how well decitabine works in treating patients with metastatic papillary thyroid cancer or follicular thyroid cancer that has stopped responding to radioactive iodine. Iodine I 131 (radioactive iodine) kills thyroid cancer cells. Metastatic thyroid cancer cells can lose the ability to be treated with radioactive iodine. Decitabine may help thyroid cancer cells regain the ability to respond to treatment with radioactive iodine.
Interventions
- DRUG Decitabine
- RADIATION Fludeoxyglucose F 18
- PROCEDURE Positron emission tomography
- RADIATION Iodine I 131
- BIOLOGICAL Recombinant thyrotropin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-05 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085293
The ClinicalTrials.gov registry entry for NCT00085293 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Decitabine is the first listed.
NCT00085293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085293 about?
NCT00085293 is a clinical study titled "Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131". This phase II trial is studying how well decitabine works in treating patients with metastatic papillary thyroid cancer or follicular thyroid cancer that has stopped responding to radioactive iodine. Iodine I 131 (radioactive iodine) kills thyroid cancer cells. Metastatic thyroid cancer cells can lo...
What is the current status of trial NCT00085293?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2004-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00085293?
The interventions under investigation include: Decitabine (DRUG), Fludeoxyglucose F 18 (RADIATION), Positron emission tomography (PROCEDURE), Iodine I 131 (RADIATION), Recombinant thyrotropin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085293?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.